Teglin Injection (Tigecycline)

• Composition :
  Each vial contains Tigecycline 50 mg.
• Indications :
  Indicated for skin & skin structure infection & intra abdominal infection.
• Pharmacodynamics :
  Tigecycline, a glycylcycline antibiotic, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. In general, tigecycline is considered bacteriostatic.
• Dosage and administration :
  The recommended dosage regimen for Teglin is an initial dose of 100 mg, followed by 50 mg every 12 hours. Intravenous infusions of Teglin should be administered over approximately 30 to 60 minutes every 12 hours. The recommended duration of treatment with Teglin for complicated skin and skin structure infections or for complicated intra-abdominal infections is 5 to 14 days. The recommended duration of treatment with Teglin for community-acquired bacterial pneumonia is 7 to 14 days. The duration of therapy should be guided by the severity and site of the infection and the patient’s clinical and bacteriological progress.
• Contraindications :
  Teglin is contraindicated for use in patients who have known hypersensitivity to tigecycline.
• Precautions and warnings :
  Anaphylaxis/anaphylactoid reactions have been reported with Teglin, and may be life-threatening. Anaphylaxis/anaphylactoid reactions have been reported with Teglin, and may be life-threatening. Hepatic dysfunction and liver failure have been reported with Teglin. Lower cure rates and higher mortality were seen when patients with ventilator-associated pneumonia were treated with Teglin. Pancreatitis, including fatalities, has been reported with Teglin. If pancreatitis is suspected, then consider stopping Teglin. The use of Teglin during tooth development may cause permanent discoloration of the teeth. Clostridium difficile associated diarrhea: evaluate if diarrhea occurs.
• Use in pregnancy, lactation & pediatrics :
  Pregnancy Category D. Pediatrics: Use in patients under 18 years of age is not recommended. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Teglin is administered to a nursing woman.
• Drug interactions :
  Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin. Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.
• Adverse reactions :
  The most common adverse reactions (incidence >5%) are nausea, vomiting, diarrhea, abdominal pain, headache, and increased SGPT.
• Therapy Area :
  Anti-Bacterials